Skip to main content
Back

Global tech and semiconductors: what’s been driving returns and what to watch next

27 April 2026

Ryan Davies, CFA Senior Portfolio Manager

Michael P. Evans, CFA Managing Director, Equity Client Portfolio Manager

Semiconductors have been one of the strongest parts of global equity markets so far in 2026, with performance supported by a powerful mix of demand and improving fundamentals. The headlines have focused on artificial intelligence (AI), but the opportunity set is broader than a single theme or a handful of companies. As AI infrastructure expands, it is driving investment not only in high-performance computing chips, but also in the networking and power technologies that keep modern data centres running. At the same time, parts of the industry outside AI are showing early signs of stabilisation and recovery.

Key points:

  • Semiconductors have led global markets in 2026, outperforming broader equities, with gains across multiple chip segments.
  • AI infrastructure is the main driver, lifting demand for compute, networking, and power-related chips.
  • Recovery is uneven beyond AI: industrial and auto are improving, while PCs and smartphones remain challenged.
  • Supply chains are becoming more resilient and localised, supporting ongoing investment in manufacturing and equipment.
  • Opportunities appear in connectivity, selective compute and power, and equipment, while risks include consumer softness, cycle swings, and potential policy or geopolitical shifts.

 

Download full PDF

 

  • Global Multi Asset Diversified Income Fund (GMADI) update amid recent Middle East developments

    Global markets turned to a risk off mode in March 2026 as rising geopolitical tensions in the Middle East eclipsed earlier optimism about growth and policy support. Equity and fixed-income markets declined as energy price shocks and uncertainty weighed on investor confidence. However, the diversified portfolio construction and income generation focus supported the Manulife Global Fund – Global Multi Asset Diversified Income Fund (“GMADI” or “the Fund”) in delivering relatively resilient performance ( 4%) .

    Read more
  • The real asset renaissance: securing power, materials, and energy in a deglobalized world

    Global supply chains are being reshaped by deglobalisation, geopolitics, and the race for energy and technological security, shifting the focus from efficiency toward resilience. In this environment of higher costs, persistent inflation pressures, and constrained supply, real assets may play an increasingly important role in helping investors navigate uncertainty and capture long‑term structural trends.

    Read more
  • Global Equity Diversified Income (GEDI) strategy: Recent update amid Middle East developments

    Despite the heightened market volatility, the Global Equities Diversified Income (GEDI) strategy has demonstrated resilience. We have made selective portfolio adjustments to address the rising risks and believe that by combining four powerful pillars—growth, value, income, and options—the strategy is well positioned to potentially deliver attractive yield alongside long-term capital growth.

    Read more
See all
  • Q&A: US equities outlook

    Michael J. Mattioli, Portfolio Manager, share his current view on US equities market, where geopolitical uncertainty and AI-driven change coexist with compelling opportunities.

    Read more
  • Navigating the global fixed-income landscape amid change: Question & Answer

    Bradley L. Lutz, Senior Portfolio Manager, and Jeffrey N. Given, Head of Developed-Market Fixed Income, share their views on global fixed income amid geopolitical risk, divergent central‑bank policies, elevated yields, currency management, and selective opportunities in a volatile market environment.

    Read more
  • 2026 Global healthcare equities outlook: Innovation supports healthcare’s long term case

    Global healthcare equities showed resilience amid 2025 volatility. The defensive characteristics, coupled with remarkable therapeutic innovations in the biopharmaceutical, MedTech, and tools sub-segments of this sector, will continue to be rewarded with capital appreciation over a full market cycle. Current valuations relative to the broader market make for an attractive entry point today, and periods like this tend to lead to outperformance for healthcare stocks over the long term.

    Read more
See all